Filed under: Major Movement , Competitive Strategy , Barrick Gold (ABX) , Commodities , Federal Reserve Back in the late 1970s, the Hunt brothers from Texas tried to corner the silver market . That drove prices to $48 an ounce. Now, 31 years later, silver is shooting higher again. The March silver futures contract closed at $32.296 per ounce , up 72 cents. Since gold is expensive, investors are turning to silver to hedge against inflation. Many fear that the Federal Reserve will not be able to control the spike in commodity prices. The Fed is buying $600 billion of treasuries and keeping interest rates near zero. Continue reading Silver Near a 31-Year High Silver Near a 31-Year High originally appeared on BloggingStocks on Sat, 19 Feb 2011 12:50:00 EST. Please see our terms for use of feeds . Permalink | Email this | Comments
Needham and Company
Riverbed Technology (NASDAQ:RVBD) in Multi-Growth Pattern for WAN
Riverbed Technology (NASDAQ:RVBD) is in a multi-year growth pattern for WAN acceleration, according to Needham, which remains positive on the company. Needham says, “…We have conviction that RVBD is in a multi-year growth pattern for WAN acceleration, as the business driver of datacenter consolidation is still very strong (though years old as a driver). Complementing the “old driver” is
Bottomline Technologies (NASDAQ:EPAY) Shares Soar on Strongest Orders in History of Company
Shares of Bottomline Technologies (NASDAQ:EPAY) were up over 12 percent on the day, as they came of their best quarter for orders in the history of the company. Needham says, “Bottomline posted by far the strongest orders quarter in the firm’s history, which is indicative of the strategic value that Bottomline provides its financial institution customers. Additionally, Q2’s robust orders
Immunogen’s (NASDAQ:IMGN) Expectations Too High, as is Valuation
Immunogen’s (NASDAQ:IMGN) valuation is too high, according to Needham, which is the result of expectations concerning late-stage T-DM1. Needham says, “We believe the current valuation is built on high expectations for the late-stage T-DM1 along with the brand-name Roche (OTC:RHHBY) (N/R) partnership, but the value creation for ImmunoGen is modest, due to the mid-single digit royalty. Despite the
Needham Positive on Biolase (NASDAQ:BLTI) over Long Term
Citing the recent restructuring of the HSIC deal, and several other postive developments, Needham says they’re postive on Biolase Technology (NASDAQ:BLTI) over the long term. Needham said, “In addition to the restructuring of the HSIC deal, the company has had a number of recent positive developments that give us reason for optimism about its long term prospects: BLTI has already received a
